iopofosine I 131 — NDA/BLA submission
mid-2027
The New Drug Application is planned for submission in mid-2027 under the FDA's Accelerated Approval Program.Source filing
CLRB biotech catalysts & pipeline
CELLECTAR BIOSCIENCES INC · Data as of 2026-09-08